Aclaris Therapeutics (ACRS) Other Non-Current Liabilities (2016 - 2026)
Aclaris Therapeutics (ACRS) posted quarterly Other Non-Current Liabilities of $1.4 million for Q1 2026, down 67.13% year-over-year from $4.3 million in Q1 2025, and down 87.13% quarter-over-quarter from $11.0 million in Q4 2025.
Aclaris Therapeutics (ACRS) Other Non-Current Liabilities (2016 - 2026) Analysis & Trends
Aclaris Therapeutics' Other Non-Current Liabilities history runs 11 years deep, the most recent figure standing at $1.4 million for Q1 2026.
- In Q1 2026, Other Non-Current Liabilities fell 67.13% year-over-year to $1.4 million; the TTM figure through Mar 2026 stood at $1.4 million (down 67.13% YoY), while the FY2025 annual figure was $11.0 million, up 147.8% from the prior year.
- Other Non-Current Liabilities for Q1 2026 stood at $1.4 million, down from $11.0 million in the prior quarter.
- The five-year high for Other Non-Current Liabilities was $33.1 million in Q4 2022, with the low at $1.4 million in Q1 2026.
- The 5-year median for Other Non-Current Liabilities is $9.2 million (2024), against an average of $13.6 million.
- The sharpest annual moves came in 2022 and 2023: Other Non-Current Liabilities soared 794.44% in 2022, then slumped 92.95% in 2023.
- Aclaris Therapeutics' Other Non-Current Liabilities stood at $33.1 million in 2022, then slumped by 90.71% to $3.1 million in 2023, then surged by 44.4% to $4.4 million in 2024, then surged by 147.8% to $11.0 million in 2025, then sank by 87.13% to $1.4 million in 2026.
- Business Quant data shows ACRS's Other Non-Current Liabilities at $1.4 million in Q1 2026, $11.0 million in Q4 2025, and $1.7 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Aclaris Therapeutics | 808.18 Mn | 716.63 Mn | 1.41 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 11.30 Mn |
| Mar 31, 2026 | 1.42 Mn |
| Dec 31, 2025 | 11.00 Mn |
| Sep 30, 2025 | 1.71 Mn |
| Jun 30, 2025 | 1.85 Mn |
| Mar 31, 2025 | 4.31 Mn |
| Dec 31, 2024 | 4.44 Mn |
| Sep 30, 2024 | 10.00 Mn |
| Jun 30, 2024 | 9.20 Mn |
| Mar 31, 2024 | 9.00 Mn |
| Dec 31, 2023 | 3.07 Mn |
| Sep 30, 2023 | 1.83 Mn |
| Jun 30, 2023 | 30.80 Mn |
| Mar 31, 2023 | 32.30 Mn |
| Dec 31, 2022 | 33.10 Mn |
| Sep 30, 2022 | 26.00 Mn |
| Jun 30, 2022 | 23.80 Mn |
| Mar 31, 2022 | 27.20 Mn |
| Dec 31, 2021 | 28.40 Mn |
| Sep 30, 2021 | 26.20 Mn |